677302-44-2

Usage

Class

Sulfonylindole compounds

Usage

Organic synthesis and pharmaceutical research

Applications

Drug discovery and development

Structure

Unique, making it a valuable building block for potential drug candidates

Biological activities

Exhibits various biological activities

Potential use

Treatment of diseases such as cancer and inflammation

Further research

May lead to the development of new and effective pharmaceuticals

Upstream product

• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 98-09-9 benzenesulfonyl chloride 

Downstream Products

• 17288-52-7 1H-pyrrolo[3,2-b]pyridine-2-carbaldehyde 
• 677302-46-4 1-(benzenesulfonyl)-4-oxido-pyrrolo[3,2-b]pyridin-4-ium 

Relevant academic research and scientific papers

Peptidylarginine deiminase inhibitor and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a peptidylarginine deiminase PAD4 inhibitor compound shown in a formula (I) or pharmaceutically acceptable salts,stereoisomers and tautomers thereof, as well as pharmaceutical compositions, pharmaceutical preparations and application thereof. X, Y, R1, R2, R3, R4, R5, R7, R8, R9, ring B and m are as defined in the specification. The compound has inhibitory effect on peptidylarginine deiminase PAD4, and can be used for treating various diseases, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, cystic fibrosis, cancer, cutaneous lupus erythematosus, asthma and psoriasis.

NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same.

Discovery of 4-azaindoles as novel inhibitors of c-Met kinase

A series of 4-azaindole inhibitors of c-Met kinase is described. The postulated binding mode was confirmed by an X-ray crystal structure and series optimisation was performed on the basis of this structure. Future directions for series development are dis

AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION

Azaindole derivatives of formula (I): wherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, for example, their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors